Krystal Biotech Logs 32% VYJUVEK Revenue Growth, Strengthens Pipeline with KB803 Enrollment
Krystal Biotech recorded $116.4 million in global VYJUVEK® net revenue in 1Q, up 32% year-over-year, with a 95% gross margin and $1.0 billion cash. Registrational KB803 corneal abrasion study is fully enrolled, KB801 neurotrophic keratitis trial continues, and FDA granted platform designations for KB407 (CF) and KB111 (HHD).
1. First Quarter Financial Results
Krystal Biotech reported $116.4 million in global VYJUVEK net product revenue for the first quarter of 2026, marking a 32% year-over-year increase; gross margin reached 95% and the company closed the quarter with $1.0 billion in cash.
2. VYJUVEK Commercial Expansion
In the United States, over 695 reimbursement approvals for VYJUVEK have been secured, with more than 570 unique prescribers since launch and 60 added in the quarter; overseas prescriptions exceed 140 in Germany, France and Japan while pricing negotiations continue for European launches.
3. Ophthalmology Pipeline Endeavors
The KB803 registrational study for corneal abrasions in DEB patients is fully enrolled with 16 participants, targeting top-line readouts in Q4 2026, and enrollment in the KB801 neurotrophic keratitis trial is ongoing with data expected by year-end.
4. Platform Designations and Respiratory Programs
The FDA granted platform technology designations to KB407 for cystic fibrosis and KB111 for HHD, streamlining future development; safety dosing for KB407 begins this month with full enrollment slated for Q2 and KB408 dose-escalation data anticipated in 2026.